Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs, used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), have seen a steady increase in demand in the Americas region.
Customer preferences: Patients suffering from respiratory diseases in the Americas region have shown a preference for bronchodilator drugs due to their quick onset of action and effectiveness in providing relief from symptoms such as shortness of breath and wheezing. Additionally, the availability of a variety of bronchodilator drugs in different formulations and delivery methods has made it easier for patients to choose the most suitable option for their needs.
Trends in the market: The United States is the largest market for bronchodilator drugs in the Americas region, with a high prevalence of respiratory diseases among the population. The market has seen a shift towards combination therapies, where bronchodilator drugs are combined with other medications such as corticosteroids for better disease management. The market has also seen an increase in the use of long-acting bronchodilators, which provide sustained relief from symptoms and reduce the frequency of exacerbations.In Brazil, the market for bronchodilator drugs has seen significant growth due to the high burden of respiratory diseases in the country. The market has seen an increase in the use of generic bronchodilator drugs due to their affordability and the government's efforts to promote their use. The market has also seen an increase in the use of nebulizers for drug delivery, especially among pediatric patients.
Local special circumstances: In Canada, the market for bronchodilator drugs has been influenced by the country's universal healthcare system, where the government negotiates drug prices with manufacturers. This has led to lower prices for bronchodilator drugs, making them more accessible to patients. The market has also seen an increase in the use of digital health technologies, such as telemedicine and mobile applications, for disease management.In Mexico, the market for bronchodilator drugs has been affected by the country's high out-of-pocket healthcare expenses, which has led to a preference for affordable generic drugs. The market has also seen an increase in the use of metered-dose inhalers, which are more convenient and easy to use compared to other drug delivery methods.
Underlying macroeconomic factors: The increasing prevalence of respiratory diseases in the Americas region, coupled with the growing aging population, has led to a higher demand for bronchodilator drugs. The rising healthcare expenditure in the region, coupled with the increasing availability of healthcare services, has also contributed to the growth of the market. The market has also been influenced by the increasing focus on research and development activities by key players in the industry, leading to the development of more effective and innovative bronchodilator drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
